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Adverse reactionAbstract Pharmacogenomics is the study of the impact of genetic variations or genotypes of
individuals on their drug response or drug metabolism. Compared to traditional genomics research,
pharmacogenomic research is more closely related to clinical practice. Pharmacogenomic
discoveries may effectively assist clinicians and healthcare providers in determining the right drugs
and proper dose for each patient, which can help avoid side effects or adverse reactions, and
improve the drug therapy. Currently, pharmacogenomic approaches have proven their utility when
it comes to the use of cardiovascular drugs, antineoplastic drugs, aromatase inhibitors, and agents
used for infectious diseases. The rapid innovation in sequencing technology and genome-wide
association studies has led to the development of numerous data resources and dramatically chan-
ged the landscape of pharmacogenomic research. Here we describe some of these web resources
along with their names, web links, main contents, and our ratings.Introduction
Pharmacogenomics, closely associated with pharmacogenetics,
is the study of genetic variations that inﬂuence the response of
individuals to drug treatment [1,2]. The major contribution
and aim of pharmacogenomics is to understand the relation-
ship between the genetic variations among individuals of
different genotypes and their reactions to drugs. This informa-
tion can be employed to determine the speciﬁc medications to
be used during the treatment of an individual patient, andthus, to enable a personalized approach to healthcare. It is well
known that a medication with proven efﬁcacy in a large patient
population may fail to show clinical beneﬁts, but cause various
adverse drug reactions (ADRs) instead, and even lead to
death in a small group of patients carrying certain genetic
variations [3].
For the past ﬁve decades, genomic and clinical scientists
have been studying samples taken from speciﬁc diseases and
drug-response phenotypes to develop a more precise method
of using medication and help prevent some of the avoidable
ADRs. Some research discoveries have already shown substan-
tial clinical beneﬁts. For patients with cardiovascular disease,
warfarin may be the most widely prescribed oral anticoagu-
lant; however, warfarin can induce serious adverse responses
like hemorrhage and undesired coagulation that may often
lead to emergency room visits [4]. Pharmacogenomic and
genome-wide association studies have dramatically changed
this situation by identifying the CYP2C9, VKORC1, andnces and
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needed for effective anticoagulation [5]. The Food and Drug
Administration (FDA) of the United States (US) revised the
drug label of warfarin in 2010, and since then, patients’ geno-
types have been taken into consideration when prescribing
warfarin [6]. Cancer pharmacogenomics is more complicated
since it must take into account both the germline and somatic
genomes of the tumor [7]. After sequencing a large amount of
kinase genes that exhibit somatic variations in tumors, phar-
macogenetic research identiﬁed a speciﬁc inhibitor, vemurafe-
nib, which can effectively prolong the survival of patients
who carry a somatic mutation in BRAF [8]. Other researchers
have shown that variations in the germline genomes of patients
are clinically relevant and may affect anti-cancer drug therapy
[9,10]. Empowered by the advances in sequencing technology
and genome-wide association studies, pharmacogenomic scien-
tists are now capable of gathering larger and more precise
amounts of genomic and clinical data. Thus, additional scien-
tiﬁc literature, popular press articles, and useful web resources
related to pharmacogenomic studies have been published in
recent years. Some of these resources associated with applica-
tions are now, or will be, an important reference in
pharmacogenomic research and clinical practice. Here we
describe some of these web resources, including their names,
web links, main contents, and an extra rating column
(Table 1). We rated these web resources based on several fac-
tors including their relations to pharmacogenomics, their data





















Note: The web resources are rated based on several factors including the reso
usefulness of the applications provided on the website, and the overall us
structure activity relationship; ADME, absorption, distribution, metabolis
P450.on the website, and the overall user experience. We hope these
web resource will extend our understanding of pharmacoge-
nomics and drug mechanisms.PharmGKB
The Pharmacogenomics Knowledgebase (PharmGKB) is a
database of genetic variations, annotations, drug pathways,
and their relationship with drug response [11]. It is a project
managed by Stanford University and supported by the NIH/
the National Institute of General Medical Sciences (NIGMS).
PharmGKB aims to help researchers to understand how genetic
variations in different individuals can affect drug reactions.
Information in the PharmGKB database is mainly derived
from the scientiﬁc literature, and is properly stored and dis-
played at different levels. The pharmacogenomic studies are
analyzed using natural language processing (NLP) technology
with manual curation of the content. To facilitate the analysis
of results, clinically-relevant information including annotations
of gene variants, pathways related to drugs, and some very
important pharmacogene (VIP) summaries are provided.
Each annotation is supported by one or more published articles
that describe the variant or genotype. Some pre-clinical data
derived from in vitro experiments and animal studies are also
collected in PharmGKB. In vitro and in vivo animal data may
not be as clinically signiﬁcant as drug testing in humans, but
it may hint at the possible, or biologically plausible, variationsMain features Rating Refs.
NLP and manual curation variants,
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prehensive genomic variation annotations, PharmGKB not
only summarizes the complicated relationship between
genotype and drug response, but also makes a deeper clinical
interpretation of varied drug responses as well as ADRs
within individuals possible. Additionally, PharmGKB also
integrates information from the Clinical Pharmacogenetics
Implementation Consortium (CPIC) to provide drug-dosing
guidelines according to personal genotype. Currently,
PharmGKB comprises information on over 26,000 genes
and over 3000 drugs, including 54 VIP summaries and
113 pharmacokinetic and pharmacodynamic pathways.
PharmGKB is updated periodically in response to newly-
published papers, and presents all its data such as variations,
annotations, summary information, and guidelines on its web-
site. PharmGKB is well known and is the preeminent resource
for translational researchers and clinical doctors to implement
pharmacogenomics information in their research or clinical
practice.
CPIC
The CPIC was formed in 2009 as a shared project of both
the Pharmacogenomics Research Network (PRN) and
PharmGKB. The CPIC aims to provide detailed gene/drug
clinical practice guidelines to promote the integration of phar-
macogenetic research into clinical practice. The CPIC collects
all levels of scientiﬁc evidence, from biological research to
clinical studies, and evaluates and incorporates this scientiﬁc
evidence into the guidelines. Rather than deﬁning the indica-
tions for testing, these CPIC guidelines will help the clinicians
understand how a genetic test can be used to optimize drug
therapy. A CPIC guideline is a comprehensive system of evi-
dence linking genotypes with phenotypes including the rules
of assigning phenotypes to genotypes, the rules of prescription
according to genotypes or phenotypes, and the strength of the
evidence. To date, the CPIC has collected 174 gene/drug pairs
of all CPIC levels, including 63 genes and 132 drugs. All CPIC
guidelines are validated by peer review, updated periodically,
and freely available via the CPIC website.
DrugBank
Unlike PharmGKB, which focuses on drug reactions accord-
ing to human genomic variations or speciﬁc genotypes, the
aim of DrugBank is to build a comprehensive resource on
drugs including their pharmacological and biochemical infor-
mation, mechanisms, and targets [12]. The ﬁrst version of
DrugBank was released in 2006 and provided data only on
selected FDA-approved drugs and their targets. With the
development and upgrading of the database, more information
is now available including, but not limited to, pharmacologi-
cal, pharmacogenomic and molecular biological, drug-food
and drug-drug interaction, metabolic enzymes, and quantita-
tive structure activity relationships (QSAR) data as well as
other drug-related data such as absorption, distribution, meta-
bolism, and excretion (ADME) proﬁles. The basic drug infor-
mation such as drug names, structures, salt-forms, targets and
actions are still being expanded upon and updated. For the
current release, DrugBank 4.0, more than 1200 drugmetabolites and more than 1300 drug metabolism reactions,
in addition to dozens of drug metabolism pathways, have also
been added to the database. In comparison to PharmGKB,
DrugBank is a comprehensive database of drugs that can
facilitate in silico drug design, drug target discovery, drug
screening or docking, interaction prediction, metabolism pre-
diction, and pharmaceutical education.
SCAN and PACdb
SCAN and PACdb are two pharmacogenomic databases
developed and published by the Pharmacogenomics of
Anticancer Agents Research group (PAAR). PAAR is a
research group focusing on pharmacokinetics and pharma-
codynamics, which aims to discover and validate functional
germline polymorphisms relevant to anticancer agents,
especially those used in the treatment of solid tumors in
adults.
SCAN is designed to collect, annotate, and present the
relationship between genotype and gene expression. It is a
large-scale genetic and genomic database containing single
nucleotide polymorphism (SNP) and copy number variation
(CNV) annotations along with a web interface, a set of meth-
ods and algorithms, and some data mining tools [13]. Data
that are stored in SCAN includes physical-based SNP annota-
tions that are categorized according to gene coordination or
linkage disequilibrium (LD) patterns, and functional SNP
annotations that are classiﬁed by their effects on expression
levels. However, the current release of SCAN only collects
data from HapMap cell lines. In addition to the SNP querying
system, SCAN also provides some follow-up analysis applica-
tions such as a genome-wide association study (GWAS) analy-
sis tool. This tool takes advantage of the tens of thousands of
correlations generated in GWAS, thus helping users of SCAN
to connect their SNP query results with their association to
diseases. Therefore, the main use of SCAN is to query the
database, to perform an analysis using the attached applica-
tions and methods, and ﬁnally, to download the result ﬁles
including SNPs, genes, and GWAS traits.
PACdb is a pharmacogenetics-cell line database collecting
pharmacology-related information including genotypes, gene
expression, and pharmacological data gathered via lym-
phoblastoid cell lines (LCL) [14]. Data in PACdb include
microarray expression data from 90 Yoruba in Ibadan,
Nigeria (YRI) and 90 Utah residents with ancestry from
northern and western Europe (CEU) LCLs, and some
microRNA data from 60 YRI and 60 CEU. PACdb set a
model on human whole genome to connect gene expression
and genotypes with cytotoxicity in LCL. PACdb may serve
as an extension to SCAN, allowing users to query for
genotypes or gene expression data with their relative drug
responses.
Human cytochrome P450 databases
Human cytochrome proteins are located either in the inner
membrane of mitochondria or in the endoplasmic reticulum
of cells [15]. Cytochrome P450 (CYP450) enzymes are present
in most tissues of the body, and they are the major enzymes
involved in drug metabolism, accounting for about 75% of
54 Genomics Proteomics Bioinformatics 13 (2015) 51–54the total metabolism [16]. The changes in CYP450 enzyme
activity may affect the metabolism of various drugs; hence,
they are a major modulator of adverse drug interactions.
The Human Cytochrome P450 Allele Nomenclature website
is a useful database that properly stores the CYP450 alleles
and the relationship between CYP450 genotypes and pheno-
types. It is also a CYP450 ofﬁcial and uniﬁed allele designation
system. Using the database, a user may easily ﬁnd a CYP450
isoform along with the nucleotide changes, trivial name, effect,
in vivo or in vitro enzyme activity, and the reference published
papers that support this record. The Cytochrome P450 Drug
Interaction Table is also a resource that contains a list of drugs
under the designation of CYP450 isoforms. These resources,
which suggest that genetic variations play a role in every step
of drug metabolism, will help researchers, clinicians, and
health care providers during their pharmacogenomic research
and clinical practice.
The pharmacogenetic website of the US FDA
Pharmacogenomic research is an important part of genomic
research that beneﬁts clinical practice since the patients’ geno-
types may help the clinicians to make better drug choices,
avoid ADRs, or to prescribe the right dose. Therefore, the
US FDA set up a speciﬁc pharmacogenetic website to label
drugs with genomic biomarkers and other information about
drug dosing or ADRs. According to the website, the factors
affecting clinical response and drug exposure variability
include adverse reaction risks, recommended dosing according
to genotypes, drug targets, disposition genes, and drug mecha-
nisms. The suggested biomarkers include somatic or germline
gene variants, expression changes, functional deﬁciencies,
and abnormalities in chromosomes. The website consists of a
table of drugs and pharmacogenomic biomarker labels
approved by the FDA. Currently, 87 out of 158 drugs recorded
in the table are labeled with different kinds of pharmacoge-
nomic information. However, the website only collects human
genetic biomarkers while disregarding bacterial or viral bio-
markers. More information and links on the drugs, such as
their usage and indications, administration and dosage, or
some box warnings, can also be found in the rest of the col-
umns of the table for further understanding of the drug and
its pharmacogenomic properties.
Conclusions
The development of sequencing technology and GWAS has
increased the feasibility and accuracy of pharmacogenomic
study, and led to the publication of a good deal of pharmaco-
genetic and pharmacogenomic literature. Scientists and
clinicians are now capable of using the web resources men-
tioned above (Table 1), along with some useful applications,
to improve several aspects of drug therapy like drug selection,
administration, and avoidance of ADRs. Nonetheless,
challenges still exist in learning how to most effectively use
the massive amount of sequencing or laboratory ﬁndings to
promote the understanding of drug mechanisms. Resolving
this issue will be the focus of pharmacogenomic researchers,
clinical doctors, computer scientists, data-mining engineers,
and database administrators in the near future.Competing interests
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